Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Scilex Holding CoSCLX · Entity 7345 | Director | October 08, 2025 | October 09, 2025 |
| Semnur Pharmaceuticals, Inc.SMNR · Entity 6623 | Director | September 22, 2025 | September 23, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Scilex Holding Co
Report date October 08, 2025 · Filed October 09, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Nonstatutory Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.58 · Expires 2035-10-08 | Direct | 20,000 |
Reported balance
After 2025-10-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-10-08 · Grant · Acquired 20,000 · Balance 20,000 F1: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Person's continued service to the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
Semnur Pharmaceuticals, Inc.
Report date September 22, 2025 · Filed September 23, 2025
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 08, 2025 Filed Oct 9, 2025 12:43 UTC | Scilex Holding Co SCLX · Entity 7345 | GrantNonstatutory Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $17.58 | $0.00 |
DisclosureSEC source: 0001193125-25-235243 · ownership.xml · derivative · entry 1 Chun Jay · CIK 0001994406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-10-08 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 22:16 UTC | Scilex Holding Co SCLX · Entity 7345 | GrantNonstatutory Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0000950170-24-137382 · ownership.xml · derivative · entry 1 Chun Jay · CIK 0001994406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-12-16 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| October 18, 2024 Filed Oct 18, 2024 20:29 UTC | Scilex Holding Co SCLX · Entity 7345 | PurchaseCommon Stock | 5,000 | $0.95 | $4,750.00 |
DisclosureSEC source: 0000950170-24-115629 · ownership.xml · nonDerivative · entry 1 Chun Jay · CIK 0001994406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,500 F1 · kind: Open market purchase by the reporting person of 5,000 shares of common stock, par value $0.0001 per share. F1 · shares: Open market purchase by the reporting person of 5,000 shares of common stock, par value $0.0001 per share. Read SEC document |
| June 20, 2024 Filed Jun 20, 2024 20:49 UTC | Scilex Holding Co SCLX · Entity 7345 | Exercise / conversionNonstatutory Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0000950170-24-075669 · ownership.xml · derivative · entry 3 Chun Jay · CIK 0001994406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 245,000 Underlying: Common Stock · 5,000 shares Expires 2033-10-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/48th of the number of shares subject to the option vested and shall vest on a monthly basis following the grant date, which was October 4, 2023, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| June 20, 2024 Filed Jun 20, 2024 20:49 UTC | Scilex Holding Co SCLX · Entity 7345 | Exercise / conversionCommon Stock | 5,000 | $1.41 | $7,050.00 |
DisclosureSEC source: 0000950170-24-075669 · ownership.xml · nonDerivative · entry 1 Chun Jay · CIK 0001994406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: 1/48th of the number of shares subject to the option vested and shall vest on a monthly basis following the grant date, which was October 4, 2023, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| May 17, 2024 Filed May 17, 2024 22:41 UTC | Scilex Holding Co SCLX · Entity 7345 | PurchaseCommon Stock | 57,500 | $0.90 | $51,640.75 |
DisclosureSEC source: 0000950170-24-062008 · ownership.xml · nonDerivative · entry 1 Chun Jay · CIK 0001994406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,500 F1 · shares: Open market purchase by the reporting person of 57,500 shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock reported represents an aggregate number of shares purchased in multiple open market transactions over a range of sales prices. F2 · price: Reflects the weighted average price of the shares of Common Stock purchased on the open market in multiple transactions on May 17, 2024 at prices ranging from $0.8978 to $0.8998 per share, inclusive. The amount reflected has been rounded to 4 decimal points. F3 · price: The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of such shares of Common Stock purchased at each separate price within such range. Read SEC document |
| October 04, 2023 Filed Oct 6, 2023 01:26 UTC | Scilex Holding Co SCLX · Entity 7345 | GrantNonstatutory Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0000950170-23-052255 · ownership.xml · derivative · entry 1 Chun Jay · CIK 0001994406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2033-10-04 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.